Skip to main content
Erschienen in: International Urology and Nephrology 1/2011

01.03.2011 | Nephrology – Original Paper

Fungal peritonitis in peritoneal dialysis: an analysis of 21 cases

verfasst von: Aydin Unal, Ismail Kocyigit, Murat Hayri Sipahioglu, Bulent Tokgoz, Oktay Oymak, Cengiz Utas

Erschienen in: International Urology and Nephrology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background and aim

Fungal peritonitis is a rare but serious complication in patients undergoing peritoneal dialysis (PD). We aimed to analyze the predisposing factors, clinical aspects, etiological agents, and treatment of fungal peritonitis in patients with PD in our hospital.

Patients and methods

The data of all patients with PD, who were followed-up between January 1995 and December 2009, were evaluated retrospectively. Twenty-one patients with fungal peritonitis were included into the study.

Results

Mean age was 46 ± 13. Twelve of the 21 patients were females. Median PD duration was 48 (range 9 to 95) months. Candida species were the most common pathogens isolated from peritoneal effluent fluid (n: 16): Candida albicans (14), Candida rugosa (n: 1), and Candida glabrata (n: 1). The other involved fungi were Aspergillus species (n: 1), Saccharomyces species (n: 1), Acromonium species (n: 1), Fusarium species (n: 1), and Rhodotorula mucilaginosa (n: 1). The PD catheter was removed in all of the patients. Median time until the PD catheter removal was 1 (range 0 to 10) day. Before 2005, this duration was 4 (0–10) days, whereas after 2005 it was 0 (0–2) days (P: 0.001). Therapy with amphotericin B and fluconazole was continued after catheter removal in 19 and in 2 of the patients, respectively. As a result of fungal peritonitis, 19 patients were transferred to hemodialysis. Two patients died during the episode of peritonitis.

Conclusions

Candida albicans was the most common pathogen. For the successful management of fungal peritonitis besides the antifungal therapy, peritoneal catheter removal was necessary in all of the patients.
Literatur
1.
Zurück zum Zitat Piraino B, Bailie GR, Bernardini J et al (2005) Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 25:107–131PubMed Piraino B, Bailie GR, Bernardini J et al (2005) Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 25:107–131PubMed
2.
Zurück zum Zitat Kim BS, Choi HY, Ryu DR et al (2005) Clinical characteristics of dialysis related sclerosing encapsulating peritonitis: multi-center experience in Korea. Yonsei Med J 46:104–111PubMedCrossRef Kim BS, Choi HY, Ryu DR et al (2005) Clinical characteristics of dialysis related sclerosing encapsulating peritonitis: multi-center experience in Korea. Yonsei Med J 46:104–111PubMedCrossRef
3.
Zurück zum Zitat Zelenitsky S, Barns L, Findlay I et al (2000) Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 36:1009–1013PubMedCrossRef Zelenitsky S, Barns L, Findlay I et al (2000) Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. Am J Kidney Dis 36:1009–1013PubMedCrossRef
4.
Zurück zum Zitat Wang AY, Yu AW, Li PK et al (2000) Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis 36:1183–1192PubMedCrossRef Wang AY, Yu AW, Li PK et al (2000) Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis 36:1183–1192PubMedCrossRef
5.
Zurück zum Zitat García-Martos P, Gil de Sola F, Marín P et al (2009) Fungal peritonitis in ambulatory continuous peritoneal dialysis: description of 10 cases. Nefrologia 29:534–539PubMed García-Martos P, Gil de Sola F, Marín P et al (2009) Fungal peritonitis in ambulatory continuous peritoneal dialysis: description of 10 cases. Nefrologia 29:534–539PubMed
6.
Zurück zum Zitat Indhumathi E, Chandrasekaran V, Jagadeswaran D et al (2009) The risk factors and outcome of fungal peritonitis in continuous ambulatory peritoneal dialysis patients. Indian J Med Microbiol 27:59–61PubMed Indhumathi E, Chandrasekaran V, Jagadeswaran D et al (2009) The risk factors and outcome of fungal peritonitis in continuous ambulatory peritoneal dialysis patients. Indian J Med Microbiol 27:59–61PubMed
7.
Zurück zum Zitat Oygar DD, Altiparmak MR, Murtezaoglu A et al (2009) Fungal peritonitis in peritoneal dialysis: risk factors and prognosis. Ren Fail 31:25–28PubMedCrossRef Oygar DD, Altiparmak MR, Murtezaoglu A et al (2009) Fungal peritonitis in peritoneal dialysis: risk factors and prognosis. Ren Fail 31:25–28PubMedCrossRef
8.
Zurück zum Zitat Bren A (1998) Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 17:839–843PubMedCrossRef Bren A (1998) Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 17:839–843PubMedCrossRef
9.
Zurück zum Zitat Bibashi E, Memmos D, Kokolina E et al (2003) Fungal peritonitis complicating peritoneal dialysis during an 11-year period: report of 46 cases. Clin Infect Dis 36:927–931PubMedCrossRef Bibashi E, Memmos D, Kokolina E et al (2003) Fungal peritonitis complicating peritoneal dialysis during an 11-year period: report of 46 cases. Clin Infect Dis 36:927–931PubMedCrossRef
10.
Zurück zum Zitat Keane WF, Bailie GR, Boeschoten E et al (2000) Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 20:396–411PubMed Keane WF, Bailie GR, Boeschoten E et al (2000) Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 20:396–411PubMed
11.
Zurück zum Zitat Matuszkiewicz-Rowinska J (2009) Update on fungal peritonitis and its treatment. Perit Dial Int 29(Suppl 2):S161–S165PubMed Matuszkiewicz-Rowinska J (2009) Update on fungal peritonitis and its treatment. Perit Dial Int 29(Suppl 2):S161–S165PubMed
12.
Zurück zum Zitat Záruba K, Peters J, Jungbluth H (1991) Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years’ experience. Am J Kidney Dis 17:43–46PubMed Záruba K, Peters J, Jungbluth H (1991) Successful prophylaxis for fungal peritonitis in patients on continuous ambulatory peritoneal dialysis: six years’ experience. Am J Kidney Dis 17:43–46PubMed
13.
Zurück zum Zitat Thodis E, Vas SI, Bargman JM et al (1998) Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 18:583–589PubMed Thodis E, Vas SI, Bargman JM et al (1998) Nystatin prophylaxis: its inability to prevent fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 18:583–589PubMed
Metadaten
Titel
Fungal peritonitis in peritoneal dialysis: an analysis of 21 cases
verfasst von
Aydin Unal
Ismail Kocyigit
Murat Hayri Sipahioglu
Bulent Tokgoz
Oktay Oymak
Cengiz Utas
Publikationsdatum
01.03.2011
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 1/2011
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-010-9763-2

Weitere Artikel der Ausgabe 1/2011

International Urology and Nephrology 1/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.